186 related articles for article (PubMed ID: 34254366)
21. Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients.
Labarrere CA; Woods JR; Hardin JW; Campana GL; Ortiz MA; Jaeger BR; Baldridge LA; Pitts DE; Kirlin PC
PLoS One; 2012; 7(4):e36100. PubMed ID: 22558345
[TBL] [Abstract][Full Text] [Related]
22. The evolving risk of sudden cardiac death after heart transplant. An analysis of the ISHLT Thoracic Transplant Registry.
Alba AC; Fan CS; Manlhiot C; Dipchand AI; Stehlik J; Ross HJ
Clin Transplant; 2019 Mar; 33(3):e13490. PubMed ID: 30697805
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection.
Zhao DX; Hu Y; Miller GG; Luster AD; Mitchell RN; Libby P
J Immunol; 2002 Aug; 169(3):1556-60. PubMed ID: 12133984
[TBL] [Abstract][Full Text] [Related]
24. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
[TBL] [Abstract][Full Text] [Related]
25. Primary Graft Dysfunction Is Associated With Development of Early Cardiac Allograft Vasculopathy, but Not Other Immune-mediated Complications, After Heart Transplantation.
Han J; Moayedi Y; Henricksen EJ; Waddell K; Valverde-Twiggs J; Kim D; Luikart H; Zhang BM; Teuteberg J; Khush KK
Transplantation; 2023 Jul; 107(7):1624-1629. PubMed ID: 36801852
[TBL] [Abstract][Full Text] [Related]
26. Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.
Loupy A; Toquet C; Rouvier P; Beuscart T; Bories MC; Varnous S; Guillemain R; Pattier S; Suberbielle C; Leprince P; Lefaucheur C; Jouven X; Bruneval P; Duong Van Huyen JP
Am J Transplant; 2016 Jan; 16(1):111-20. PubMed ID: 26588356
[TBL] [Abstract][Full Text] [Related]
27. Increased fibrosis and microvessel disease in allograft endomyocardial biopsies of children with chronic graft failure due to cardiac allograft vasculopathy.
Watanabe K; Husain N; Arzu JL; Wechsler JB; Arva NC
Cardiovasc Pathol; 2023; 63():107509. PubMed ID: 36442702
[TBL] [Abstract][Full Text] [Related]
28. Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathy.
Coutance G; Ouldamar S; Rouvier P; Saheb S; Suberbielle C; Bréchot N; Hariri S; Lebreton G; Leprince P; Varnous S
J Heart Lung Transplant; 2015 Aug; 34(8):1050-7. PubMed ID: 25956740
[TBL] [Abstract][Full Text] [Related]
29. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy.
Heikal NM; Bader FM; Martins TB; Pavlov IY; Wilson AR; Barakat M; Stehlik J; Kfoury AG; Gilbert EM; Delgado JC; Hill HR
Transplant Proc; 2013; 45(1):376-82. PubMed ID: 23267802
[TBL] [Abstract][Full Text] [Related]
30. Cardiac magnetic resonance assessment of acute rejection and cardiac allograft vasculopathy in pediatric heart transplant.
Kikano S; Lee S; Dodd D; Godown J; Bearl D; Chrisant M; Chan KC; Nandi D; Damon B; Samyn MM; Yan K; Crum K; George-Durrett K; Hernandez L; Soslow JH
J Heart Lung Transplant; 2024 May; 43(5):745-754. PubMed ID: 38141894
[TBL] [Abstract][Full Text] [Related]
31. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy.
Stoica SC; Cafferty F; Pauriah M; Taylor CJ; Sharples LD; Wallwork J; Large SR; Parameshwar J
J Heart Lung Transplant; 2006 Apr; 25(4):420-5. PubMed ID: 16563972
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy.
Bellumkonda L; Patel J
Clin Transplant; 2020 Jan; 34(1):e13769. PubMed ID: 31829455
[TBL] [Abstract][Full Text] [Related]
33. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
[TBL] [Abstract][Full Text] [Related]
34. Association of MICA and AT1R antibodies with antibody-mediated rejection and cardiac allograft vasculopathy in a pediatric heart transplant recipient.
Chou-Wu E; Kemna M; Ross S; Youngs D; Law Y; Gimferrer I
Transpl Immunol; 2023 Jun; 78():101811. PubMed ID: 36889546
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients.
Vrtovec B; Haddad F; Pham M; Deuse T; Fearon WF; Schrepfer S; Leon S; Vu T; Valantine H; Hunt SA
Transplant Proc; 2013; 45(6):2406-9. PubMed ID: 23953556
[TBL] [Abstract][Full Text] [Related]
37. Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function.
Grimm K; Lehner A; Fernandez Rodriguez S; Orban M; Fischer M; Rosenthal LL; Jakob A; Haas NA; Dalla Pozza R; Kozlik-Feldmann R; Ulrich SM
Clin Transplant; 2021 Mar; 35(3):e14191. PubMed ID: 33315277
[TBL] [Abstract][Full Text] [Related]
38. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study.
Loupy A; Coutance G; Bonnet G; Van Keer J; Raynaud M; Aubert O; Bories MC; Racapé M; Yoo D; Duong Van Huyen JP; Bruneval P; Taupin JL; Lefaucheur C; Varnous S; Leprince P; Guillemain R; Empana JP; Levine R; Naesens M; Patel JK; Jouven X; Kobashigawa J
Circulation; 2020 Jun; 141(24):1954-1967. PubMed ID: 32363949
[TBL] [Abstract][Full Text] [Related]
39. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
40. Improved Detection of Cardiac Allograft Vasculopathy: A Multi-Institutional Analysis of Functional Parameters in Pediatric Heart Transplant Recipients.
Kindel SJ; Law YM; Chin C; Burch M; Kirklin JK; Naftel DC; Pruitt E; Carboni MP; Arens A; Atz AM; Dreyer WJ; Mahle WT; Pahl E
J Am Coll Cardiol; 2015 Aug; 66(5):547-57. PubMed ID: 26227194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
